ISSN 2575-6206
Vol. 6, Issue 1, 2022March 17, 2022 CDT
Immunotherapy using CRISPR-Cas9 systems to treat rheumatoid arthritis with PTPN22 R620W mutations and target PD-1 and CD20
Immunotherapy using CRISPR-Cas9 systems to treat rheumatoid arthritis with PTPN22 R620W mutations and target PD-1 and CD20
Articles in Vol. 6, Issue 1, 2022
Vol. 6, Issue 1, 2022
- Immunotherapy using CRISPR-Cas9 systems to treat rheumatoid arthritis with PTPN22 R620W mutations and target PD-1 and CD20Aishwarya ShivaramanNicole Guilz
- Gender disparity in the incidence of childhood central nervous system cancers among different Asian Pacific Islander populationsAlistair Lam
- Dimensionality reduction of the freedoms constituting The Index of Economic Freedom.Eric Cui
- Sentiment Analysis on Tweets in the 2020 US Presidential ElectionArmaan Chandak
- Natural product polyphenol inhibition of amyloid-β aggregationVarsha BeldonaAyush PatelKavya PatelNeha AbrahamAlyssa HalvorsenAshlee LiuNandini MannemGayathri Renganathan
- Prodrugs: A Comparison of o-Nitrobenzyl, p-Hydroxyphenacyl, and Coumarin Photoremovable Protecting Groups and Their In Vivo Applications in Cancer TherapyEmma Ka
- COVID-19 Variants: A Structural and Functional Analysis of Spike ProteinsHarshni P PatelMicki ZhengRakhi AgarwalNadia MakarJennifer DonnellyMina Armani
Shivaraman, Aishwarya, and Nicole Guilz. 2022. “Immunotherapy Using CRISPR-Cas9 Systems to Treat Rheumatoid Arthritis with PTPN22 R620W Mutations and Target PD-1 and CD20.” Journal of High School Science 6 (1). https://doi.org/10.64336/001c.33705.